相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2022)
The management of metastatic GIST: current standard and investigational therapeutics
Ciara M. Kelly et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).
Yoshitaka Honma et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
Yoon-Koo Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
John R. Zalcberg et al.
ONCOLOGIST (2021)
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors A Phase 1b/2a Nonrandomized Clinical Trial
Andrew J. Wagner et al.
JAMA ONCOLOGY (2021)
Ripretinib for the treatment of advanced gastrointestinal stromal tumor
John R. Zalcberg
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)
Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward
M. Julia Lostes-Bardaji et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit inPatients WithRefractory Gastrointestinal Stromal Tumors A Phase 1b/2a Nonrandomized Clinical Trial
Andrew J. Wagner et al.
JAMA ONCOLOGY (2021)
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
Hans Gelderblom et al.
BRITISH JOURNAL OF CANCER (2020)
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2020)
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Michael C Heinrich et al.
LANCET ONCOLOGY (2020)
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
Filip Janku et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Secondary KIT mutations: the GIST of drug resistance and sensitivity
Andrea Napolitano et al.
BRITISH JOURNAL OF CANCER (2019)
First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors
Akihiko Shimomura et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial
Toshihiko Doi et al.
EUROPEAN JOURNAL OF CANCER (2019)
Gastrointestinal stromal tumors: a comprehensive review
Trisha M. Parab et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2018)
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene
Valentina Indio et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Gastrointestinal Stromal Tumors: The GIST of Precision Medicine
Lin Mei et al.
TRENDS IN CANCER (2018)
Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor
Phillip Zook et al.
CLINICAL CANCER RESEARCH (2017)
Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors
Amber E. Bannon et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2017)
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels
Paolo G. Casali et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review
Peter J. Oppelt et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)
Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review
Antonia Dimitrakopoulou-Strauss et al.
CLINICAL AND TRANSLATIONAL IMAGING (2017)
Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies
Kjetil Soreide et al.
CANCER EPIDEMIOLOGY (2016)
Molecular and morphological correlation in gastrointestinal stromal tumours (GISTs): an update and primer
Runjan Chetty et al.
JOURNAL OF CLINICAL PATHOLOGY (2016)
Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic
Sosipatros A. Boikos et al.
JAMA ONCOLOGY (2016)
Paraganglioma and phaeochromocytoma: from genetics to personalized medicine
Judith Favier et al.
NATURE REVIEWS ENDOCRINOLOGY (2015)
Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy
Thomas Van Looy et al.
CLINICAL CANCER RESEARCH (2014)
A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal
Giuseppe Floris et al.
CLINICAL CANCER RESEARCH (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Inhibition of HSP90 molecular chaperones: moving into the clinic
Rocio Garcia-Carbonero et al.
LANCET ONCOLOGY (2013)
BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance
G. S. Falchook et al.
ONCOTARGET (2013)
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
Philippe A. Cassier et al.
CLINICAL CANCER RESEARCH (2012)
Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
Suzanne George et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors
Jose Gaal et al.
MODERN PATHOLOGY (2011)
Gastrointestinal stromal tumours: origin and molecular oncology
Christopher L. Corless et al.
NATURE REVIEWS CANCER (2011)
Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 Cases
Lizhi Zhang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
P. Schoffski et al.
ANNALS OF ONCOLOGY (2010)
Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
Martine Van Glabbeke
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
Axel Le Cesne et al.
LANCET ONCOLOGY (2010)
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S. George et al.
EUROPEAN JOURNAL OF CANCER (2009)
Gastrointestinal Stromal Tumors (GIST) in Children and Adolescents: A Comprehensive Review of the Current Literature
Martin Benesch et al.
PEDIATRIC BLOOD & CANCER (2009)
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
Narasimhan P. Agaram et al.
GENES CHROMOSOMES & CANCER (2008)
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours
J. Lasota et al.
HISTOPATHOLOGY (2008)
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases
Jerzy Lasota et al.
MODERN PATHOLOGY (2008)
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD
Barbara Pasini et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2008)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor
Sebastian Bauer et al.
CANCER RESEARCH (2006)
KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)
Jerzy Lasota et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2006)
GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology
J Lasota et al.
LABORATORY INVESTIGATION (2006)
Gastrointestinal stromal tumors in patients with neurofibromatosis 1 - A clinicopothologic and molecular genetic study of 45 cases
M Miettinen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2006)
Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors:: A study by the Spanish Group for Sarcoma Research (GEIS)
J Martín et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib
CL Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
JR Zalcberg et al.
EUROPEAN JOURNAL OF CANCER (2005)
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
M Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2004)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors
LL Chen et al.
CANCER RESEARCH (2004)
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings
H Choi et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Clinical management of gastrointestinal stromal tumors: Before and after STI-571
RP DeMatteo et al.
HUMAN PATHOLOGY (2002)
Familial paraganglioma and gastric stromal sarcoma: A new syndrome distinct from the Carney triad
JA Carney et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2002)
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
ML Lux et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
